yahoo_financeOriginal article
OKYO Pharma Receives 'Positive Feedback' From FDA Meeting About Phase 3 Trial of Urcosimod to Treat Neuropathic Corneal Pain
Phase 3positiveurcosimodPositive
AI Analysis
Summary
OKYO Pharma received positive feedback from the FDA regarding its Phase 3 trial of urcosimod for treating neuropathic corneal pain. The company had an FDA meeting to discuss the trial program.
Clinical Trial Data
Phase
Phase 3
Outcome Details
Positive feedback from FDA meeting
Importance:6/10
Sentiment:
0.70
FDA feedbackPhase 3urcosimodneuropathic corneal painophthalmology
Related Companies
Read the original article
Published by yahoo_finance on July 8, 2026 11:28 AM